Price T Rowe Associates Inc Mirati Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $101 Million - $149 Million	-2,394,968 Reduced 98.44%	38,061 $2.24 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $18.2 Million - $29.7 Million	655,450 Added 36.87%	2,433,029 $106 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $239,830 - $328,514	6,638 Added 0.37%	1,777,579 $64.2 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $12.9 Million - $19.2 Million	354,213 Added 25.0%	1,770,941 $65.8 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $11.3 Million - $27 Million	273,973 Added 23.97%	1,416,728 $64.2 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $5.43 Million - $7.91 Million	91,225 Added 8.68%	1,142,755 $79.8 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $23.2 Million - $52.6 Million	-592,686 Reduced 36.05%	1,051,530 $70.6 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $40.2 Million - $80.1 Million	-530,583 Reduced 24.4%	1,644,216 $135 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $8 Million - $11.5 Million	60,589 Added 2.87%	2,174,799 $319 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $25.4 Million - $34.1 Million	192,431 Added 10.01%	2,114,210 $374 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $56.1 Million - $70 Million	389,279 Added 25.4%	1,921,779 $310 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $4.28 Million - $5.96 Million	-26,916 Reduced 1.73%	1,532,500 $263 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $253 Million - $375 Million	1,559,416 New	1,559,416 $343 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.